Document is current
Any future updates will be listed below
-
Authors
Benhar, Inbal https://orcid.org/0000-0002-0239-2162
Ding, Jiarui https://orcid.org/0000-0003-3670-7764
Yan, Wenjun https://orcid.org/0000-0003-3568-4265
Whitney, Irene E.
Jacobi, Anne
Sud, Malika https://orcid.org/0000-0001-9258-7029
Burgin, Grace
Shekhar, Karthik
Tran, Nicholas M.
Wang, Chen
He, Zhigang https://orcid.org/0000-0001-6080-6880
Sanes, Joshua R.
Regev, Aviv https://orcid.org/0000-0003-3293-3158
- License Information
-
More Information
Article History
Received: 14 June 2022
Accepted: 13 January 2023
First Online: 20 February 2023
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and, until 31 August 2020, was a SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From 1 August 2020, A.R. is an employee of Genentech and has equity in Roche. J.R.S. is a consultant for Biogen. Z.H. is an advisor of Myro Therapeutics, Axonis and Rugen Therapeutics. The remaining authors declare no competing interests.
